Preventing cystic fibrosis in the RSA.
Prenatal diagnostic testing for cystic fibrosis (CF) in South Africa has been available by microvillar enzyme (MVE) assay since 1984 and by DNA investigation since 1987. The advantages and practical uses of these two procedures are reviewed. Over the period 1984-1989, 59 MVE assays and 13 DNA investigations (1 woman had both done; total number of pregnancies tested 71) were performed for the prenatal diagnosis of CF in high-risk families. Of the 71 pregnancies tested (65 white woman, 4 mixed race and 2 Indian), 18 fetuses were found to be affected: of these, 15 couples chose to have the pregnancies terminated. In 2 fetuses tested the MVE assays were 'equivocal' and the babies were born affected. By using population genetic and demographic data it is estimated that the present rate of prenatal diagnosis and prevention satisfies about one-quarter of the projected and practically achievable annual need. It is also tentatively shown that only about 60% of the projected number of high-risk families are at present on record. It is concluded that more systematic efforts should be directed at carefully guided information and awareness campaigns, in order to draw more CF families into the mainstream of voluntary genetic services. The identification and cloning of the CF gene (in 1989) has made it possible to extend considerably the present strategy of prevention and to include lower-risk and extended CF families in due time.
Hitzeroth
H W
HW
Genetic Services, Department of National Health and Population Development, Pretoria.
Petersen
E M
EM
Herbert
J
J
Denter
M
M
D000653:Amniotic Fluid / Q000201:enzymology*; D044383:Black People; D004796:Clinical Enzyme Tests; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000517:prevention & control*; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis*; D005819:Genetic Markers; D006801:Humans; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods*; D013019:South Africa; D044465:White People
D005819:Genetic Markers